Pieris Pharmaceuticals Growth, Revenue, Number of Employees and Funding

Overview

Location:
Boston, MA USA
Total Funding:$16.5M
Industry:Biotech
Founded:2001
Lead Investor(s):N/A
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Pieris Pharmaceuticals's estimated revenue is currently $14.4M per year.
  • Pieris Pharmaceuticals received $50.6M in venture funding in February 2018.
  • Pieris Pharmaceuticals's estimated revenue per employee is $144150
  • Pieris Pharmaceuticals's total funding is $16.5M.

Employee Data

  • Pieris Pharmaceuticals has 100 Employees.
  • Pieris Pharmaceuticals grew their employee count by 15% last year.
  • Pieris Pharmaceuticals currently has 9 job openings.

Executive Contacts

NameTitle
Simon HsuExecutive Director, CMC
Tom BuresVP Finance
Ahmed MousaVice President, General Counsel & Corporate Secretary
Louis MatisChief Development Officer
Antoine GalouSenior Director, Business Development and Portfolio Managament
Stephen YoderPresident/CEO
Shane OlwillVP/Head of Development/Immuno-Oncology
Mary FitzgeraldVP Respiratory Medicine
Christine RotheVP/Head of Discovery & Alliance Management
Eckhard NiemeierVP/Head of Business Development

What Is Pieris Pharmaceuticals?

Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. Pieris is currently hiring in Boston and Freising, Germany. See here for our full list of job openings and information on applying: https://www.pieris.com/careers

keywords:Biotechnology,Healthcare,Pharmaceuticals

100

Number of Employees

$14.4M

Revenue (est)

9

Current Jobs

15%

Employee Growth %

$16.5M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$6.7M4659%
Tango Therapeut...
$8.4M5841%$55M
Compass Therape...
$14.7M10215%
Hamilton Storag...
$13.6M949%
Alnylam Pharmac...
$74.9M122831%$417.5M
Axcella
$8.2M5719%
Berkshire Corpo...
$10.7M7412%
Repligen Corpor...
$47M32422%$242.6M
Allena Pharmace...
$6M5019%$93M
ABclonal Techno...
$7.9M5531%

Pieris Pharmaceuticals News

09/09/2019 - BNP Paribas Arbitrage SA Sells 4466 Shares of Pieris ...

BNP Paribas Arbitrage SA decreased its holdings in Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 41.3% during the 2nd quarter, according to ...

09/03/2019 - Pieris Pharmaceuticals Announces Changes to Senior ...

BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company ...

08/29/2019 - Pieris Pharmaceuticals to Participate in Upcoming Investor ...

About Pieris Pharmaceuticals: Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to ...

Pieris Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2016-06-20$16.5MUndisclosedArticle
2018-02-22$50.6MUndisclosedArticle

Pieris Pharmaceuticals Executive Hires

DateNameTitleReference
2016-12-02Claude KnopfSVP/Chief Business OfficerArticle
2017-08-11Allan ReineSVP/CFOArticle
2017-10-13Ingmar BrunsVice President of Clinical DevelopmentArticle
2017-11-22James GeraghtyChairmanArticle